

Drug Monograph

Drug / Drug Class: **Angeliq® (drospirenone and estradiol) tablet / Estrogen / Progestin Combination Hormone Replacement Therapy**

Prepared for: MO HealthNet
Prepared by: Xerox Heritage, LLC

New Criteria **Revision of Existing Criteria**

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Each 28 day treatment pack of Angeliq® contains 0.25 mg drospirenone and 0.5 mg estradiol or 0.5 mg drospirenone and 1 mg estradiol per tablet.

Manufacturer: For: Bayer HealthCare Pharmaceuticals Inc. Wayne, NJ 07470

Indications: Angeliq® is an estrogen / progestin combination indicated for the treatment of moderate to severe vasomotor symptoms due to menopause in women who have a uterus. Angeliq® is also indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause in women who have a uterus.

Costs: \$83.44 per 28 tablet pack of Angeliq® Wholesale Acquisition Cost

Summary of Findings: MO HealthNet Division recommends Open Access status for this product.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Clinical Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred Agent
 Appropriate Indications No PA Required

Prepared By: Robyn Phipps, Pharm. D. Candidate
Date: September 24, 2012